Factors influencing daily treatment choices in multiple
sclerosis: practice guidelines, biomarkers and burden of
disease

J 2020

Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease

BERGER, Thomas, Monika ADAMCZYK-SOWA, Tunde CSEPANY, Franz FAZEKAS, Tanja Hojs FABJAN et. al.

Základní údaje

Originální název

Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease

Autoři

BERGER, Thomas (40 Rakousko, garant), Monika ADAMCZYK-SOWA (616 Polsko), Tunde CSEPANY (348 Maďarsko), Franz FAZEKAS (620 Portugalsko), Tanja Hojs FABJAN (705 Slovinsko), Dana HORAKOVA (203 Česká republika), Alenka Horvat LEDINEK (705 Slovinsko), Zsolt ILLES (208 Dánsko), Gisela KOBELT (752 Švédsko), Sasa Sega JAZBEC (705 Slovinsko), Eleonora KLIMOVA (703 Slovensko), Fritz LEUTMEZER (620 Portugalsko), Konrad REJDAK (616 Polsko), Csilla ROZSA (348 Maďarsko), Johann SELLNER (40 Rakousko), Krzysztof SELMAJ (616 Polsko), Pavel ŠTOURAČ (203 Česká republika, domácí), Jarmila SZILASIOVA (703 Slovensko), Peter TURCANI (703 Slovensko), Marta VACHOVA (203 Česká republika), Manuela VANECKOVA (203 Česká republika), Laszlo VECSEI (348 Maďarsko) a Eva Kubala HAVRDOVA (203 Česká republika)

Vydání

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, LONDON, SAGE PUBLICATIONS LTD, 2020, 1756-2856

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30103 Neurosciences

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.570

Kód RIV

RIV/00216224:14110/20:00117694

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1177/1756286420975223

UT WoS

000597939700001

Klíčová slova anglicky

biomarkers; burden of disease; cognitive dysfunction; magnetic resonance imaging; multiple sclerosis; neurofilament

Štítky

14110221, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 1. 2021 10:29, Mgr. Tereza Miškechová

Anotace

V originále

At two meetings of a Central European board of multiple sclerosis (MS) experts in 2018 and 2019 factors influencing daily treatment choices in MS, especially practice guidelines, biomarkers and burden of disease, were discussed. The heterogeneity of MS and the complexity of the available treatment options call for informed treatment choices. However, evidence from clinical trials is generally lacking, particularly regarding sequencing, switches and escalation of drugs. Also, there is a need to identify patients who require highly efficacious treatment from the onset of their disease to prevent deterioration. The recently published European Committee for the Treatment and Research in Multiple Sclerosis/European Academy of Neurology clinical practice guidelines on pharmacological management of MS cover aspects such as treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and are based on expert consensus statements. However, the recommendations constitute an excellent framework that should be adapted to local regulations, MS center capacities and infrastructure. Further, available and emerging biomarkers for treatment guidance were discussed. Magnetic resonance imaging parameters are deemed most reliable at present, even though complex assessment including clinical evaluation and laboratory parameters besides imaging is necessary in clinical routine. Neurofilament-light chain levels appear to represent the current most promising non-imaging biomarker. Other immunological data, including issues of immunosenescence, will play an increasingly important role for future treatment algorithms. Cognitive impairment has been recognized as a major contribution to MS disease burden. Regular evaluation of cognitive function is recommended in MS patients, although no specific disease-modifying treatment has been defined to date. Finally, systematic documentation of real-life data is recognized as a great opportunity to tackle unresolved daily routine challenges, such as use of sequential therapies, but requires joint efforts across clinics, governments and pharmaceutical companies.

Citovat

BERGER, Thomas, Monika ADAMCZYK-SOWA, Tunde CSEPANY, Franz FAZEKAS, Tanja Hojs FABJAN, Dana HORAKOVA, Alenka Horvat LEDINEK, Zsolt ILLES, Gisela KOBELT, Sasa Sega JAZBEC, Eleonora KLIMOVA, Fritz LEUTMEZER, Konrad REJDAK, Csilla ROZSA, Johann SELLNER, Krzysztof SELMAJ, Pavel ŠTOURAČ, Jarmila SZILASIOVA, Peter TURCANI, Marta VACHOVA, Manuela VANECKOVA, Laszlo VECSEI a Eva Kubala HAVRDOVA. Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. LONDON: SAGE PUBLICATIONS LTD, 2020, roč. 13, DEC 2020, s. 1-13. ISSN 1756-2856. Dostupné z: https://dx.doi.org/10.1177/1756286420975223.

@article{1725937,
   author = {Berger, Thomas and AdamczykandSowa, Monika and Csepany, Tunde and Fazekas, Franz and Fabjan, Tanja Hojs and Horakova, Dana and Ledinek, Alenka Horvat and Illes, Zsolt and Kobelt, Gisela and Jazbec, Sasa Sega and Klimova, Eleonora and Leutmezer, Fritz and Rejdak, Konrad and Rozsa, Csilla and Sellner, Johann and Selmaj, Krzysztof and Štourač, Pavel and Szilasiova, Jarmila and Turcani, Peter and Vachova, Marta and Vaneckova, Manuela and Vecsei, Laszlo and Havrdova, Eva Kubala},
   article_location = {LONDON},
   article_number = {DEC 2020},
   doi = {http://dx.doi.org/10.1177/1756286420975223},
   keywords = {biomarkers; burden of disease; cognitive dysfunction; magnetic resonance imaging; multiple sclerosis; neurofilament},
   language = {eng},
   issn = {1756-2856},
   journal = {THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS},
   title = {Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease},
   url = {https://journals.sagepub.com/doi/pdf/10.1177/1756286420975223},
   volume = {13},
   year = {2020}
}

TY  - JOUR
ID  - 1725937
AU  - Berger, Thomas - Adamczyk-Sowa, Monika - Csepany, Tunde - Fazekas, Franz - Fabjan, Tanja Hojs - Horakova, Dana - Ledinek, Alenka Horvat - Illes, Zsolt - Kobelt, Gisela - Jazbec, Sasa Sega - Klimova, Eleonora - Leutmezer, Fritz - Rejdak, Konrad - Rozsa, Csilla - Sellner, Johann - Selmaj, Krzysztof - Štourač, Pavel - Szilasiova, Jarmila - Turcani, Peter - Vachova, Marta - Vaneckova, Manuela - Vecsei, Laszlo - Havrdova, Eva Kubala
PY  - 2020
TI  - Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease
JF  - THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
VL  - 13
IS  - DEC 2020
SP  - 1-13
EP  - 1-13
PB  - SAGE PUBLICATIONS LTD
SN  - 17562856
KW  - biomarkers
KW  - burden of disease
KW  - cognitive dysfunction
KW  - magnetic resonance imaging
KW  - multiple sclerosis
KW  - neurofilament
UR  - https://journals.sagepub.com/doi/pdf/10.1177/1756286420975223
L2  - https://journals.sagepub.com/doi/pdf/10.1177/1756286420975223
N2  - At two meetings of a Central European board of multiple sclerosis (MS) experts in 2018 and 2019 factors influencing daily treatment choices in MS, especially practice guidelines, biomarkers and burden of disease, were discussed. The heterogeneity of MS and the complexity of the available treatment options call for informed treatment choices. However, evidence from clinical trials is generally lacking, particularly regarding sequencing, switches and escalation of drugs. Also, there is a need to identify patients who require highly efficacious treatment from the onset of their disease to prevent deterioration. The recently published European Committee for the Treatment and Research in Multiple Sclerosis/European Academy of Neurology clinical practice guidelines on pharmacological management of MS cover aspects such as treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and are based on expert consensus statements. However, the recommendations constitute an excellent framework that should be adapted to local regulations, MS center capacities and infrastructure. Further, available and emerging biomarkers for treatment guidance were discussed. Magnetic resonance imaging parameters are deemed most reliable at present, even though complex assessment including clinical evaluation and laboratory parameters besides imaging is necessary in clinical routine. Neurofilament-light chain levels appear to represent the current most promising non-imaging biomarker. Other immunological data, including issues of immunosenescence, will play an increasingly important role for future treatment algorithms. Cognitive impairment has been recognized as a major contribution to MS disease burden. Regular evaluation of cognitive function is recommended in MS patients, although no specific disease-modifying treatment has been defined to date. Finally, systematic documentation of real-life data is recognized as a great opportunity to tackle unresolved daily routine challenges, such as use of sequential therapies, but requires joint efforts across clinics, governments and pharmaceutical companies.
ER  -

BERGER, Thomas, Monika ADAMCZYK-SOWA, Tunde CSEPANY, Franz FAZEKAS, Tanja Hojs FABJAN, Dana HORAKOVA, Alenka Horvat LEDINEK, Zsolt ILLES, Gisela KOBELT, Sasa Sega JAZBEC, Eleonora KLIMOVA, Fritz LEUTMEZER, Konrad REJDAK, Csilla ROZSA, Johann SELLNER, Krzysztof SELMAJ, Pavel ŠTOURAČ, Jarmila SZILASIOVA, Peter TURCANI, Marta VACHOVA, Manuela VANECKOVA, Laszlo VECSEI a Eva Kubala HAVRDOVA. Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. \textit{THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS}. LONDON: SAGE PUBLICATIONS LTD, 2020, roč.~13, DEC 2020, s.~1-13. ISSN~1756-2856. Dostupné z: https://dx.doi.org/10.1177/1756286420975223.

Podrobný výpis o publikaci